← The Wire·Breaking·Consumer·

FDA approves Roivant's LISRAYA for dermatomyositis; drug now available in U.S.

Roivant said the FDA approved once-daily LISRAYA for adults with dermatomyositis, with the pill now available in the United States. The approval opens a commercial opportunity, but the company’s latest reported revenue was $8.3M, down 71.6% year over year, against a net margin of -3629.2%.

GLOBENEWSWIRE / FILE

The story

The FDA has approved Roivant's LISRAYA, a 30 mg once-daily pill for adults with dermatomyositis, the company said Thursday. Roivant announced that the treatment is now available in the U.S., marking the regulatory transition from development to commercial distribution for brepocitinib in this indication.

The approval gives Roivant a marketed product in a rare autoimmune disease, but it arrives against a weak financial base. For the fiscal year ended March 31, 2026, Roivant reported revenue of $8.3M, down 71.6% year over year, and diluted EPS of $-0.54. Its reported net margin was -3629.2%, underscoring that the approval must ultimately translate into prescriptions and revenue rather than serving only as a regulatory milestone.

The direct company exposure is Roivant, whose commercial opportunity now depends on LISRAYA's launch. The mechanism is straightforward: U.S. availability creates the possibility of product revenue from adults with dermatomyositis, while the company's existing losses mean launch execution, patient access and reimbursement will determine how quickly that opportunity affects the financial statements.

Key questions remain around how rapidly physicians will adopt LISRAYA and how much revenue the indication can generate. The latest financial figures therefore provide important context for evaluating the potential commercial contribution from the newly approved product.

The next evidence should come from Roivant's disclosures on launch progress and from its next reported financial results. Investors will need prescription, revenue and cash-burn data to determine whether U.S. availability is producing a meaningful change from the $8.3M revenue base. The timing and scale of any commercial update, as well as management's discussion of LISRAYA's rollout, remain the key open points.

Our read · Thu, Aug 27

Roivant (ROIV) said the FDA approved once-daily LISRAYA for adults with dermatomyositis, and the pill is now available in the United States.

Why. The approval creates a new revenue pathway, but the financial consequence depends on launch execution that has not yet been quantified. With revenue at $8.3M, down 71.6% year over year, and a net margin of -3629.2%, the next commercial update is more important than the regulatory headline itself.

Both cases

The case it holdsFDA approval and immediate U.S. availability give Roivant a concrete commercial product that could begin reversing the $8.3M revenue base.
The case it breaksThe bear case is that approval produces little near-term financial relief because the announcement supplies no launch forecast, prescription data or pricing information while diluted EPS remains $-0.54.

What could change this view: The trade fails if U.S. availability does not produce measurable prescriptions or revenue, leaving Roivant’s sharply negative profitability profile unchanged.

Roivant Sciences stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 1

Keep reading

Latest on the Wire

Iran claims strikes on two US bases in Bahrain as Trump line is testedTrump calls Russian missiles in Poland mistakes before fresh incursionAmazon nears $7.5bn Decart deal as AWS takes on Nvidia in AI computingRussian cargo ship Sparta II reportedly hit by drones near FinlandBTCS warns $54 million Aave loan faces liquidation as ether fallsContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on Thursday
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by GlobeNewswire as Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S., . Who answers for this

The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →